anmelden
OMX Nordic 40
2.675,31
PKT
+57,36
PKT
+2,19
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Nordic 40-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.01.26 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 29.01.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 29.01.26 | Nokia Neutral | UBS AG | |
| 29.01.26 | Hennes Mauritz (H M, H&M) Hold | Jefferies & Company Inc. | |
| 29.01.26 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 29.01.26 | Nokia Buy | Jefferies & Company Inc. | |
| 29.01.26 | Volvo (B) Overweight | JP Morgan Chase & Co. | |
| 28.01.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 28.01.26 | Volvo (B) Buy | Jefferies & Company Inc. | |
| 28.01.26 | Volvo (B) Outperform | RBC Capital Markets | |
| 28.01.26 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 28.01.26 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 27.01.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 27.01.26 | Volvo (B) Buy | Jefferies & Company Inc. | |
| 26.01.26 | Hennes Mauritz (H M, H&M) Sector Perform | RBC Capital Markets | |
| 23.01.26 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 23.01.26 | Ericsson (Telefon L.M.Ericsson) (B) Underperform | Bernstein Research | |
| 23.01.26 | Ericsson (Telefon L.M.Ericsson) (B) Sell | UBS AG | |
| 23.01.26 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 22.01.26 | A.P. Moeller - Maersk A-S (B) Underweight | JP Morgan Chase & Co. | |
| 22.01.26 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 22.01.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 22.01.26 | Volvo (B) Market-Perform | Bernstein Research | |
| 21.01.26 | Novo Nordisk Neutral | UBS AG | |
| 21.01.26 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 20.01.26 | Volvo (B) Buy | UBS AG | |
| 20.01.26 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
| 20.01.26 | Novo Nordisk Neutral | UBS AG | |
| 20.01.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 16.01.26 | Novo Nordisk Buy | Deutsche Bank AG | |
| 16.01.26 | AstraZeneca Buy | UBS AG | |
| 16.01.26 | AstraZeneca Sell | Deutsche Bank AG | |
| 16.01.26 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 15.01.26 | AstraZeneca Overweight | Barclays Capital | |
| 15.01.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 15.01.26 | Nokia Overweight | Morgan Stanley | |
| 15.01.26 | Novo Nordisk Neutral | UBS AG | |
| 15.01.26 | ABB (Asea Brown Boveri) Market-Perform | Bernstein Research | |
| 15.01.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 15.01.26 | Novo Nordisk Overweight | JP Morgan Chase & Co. |